Essex Woodlands Management, Inc. purchased $21.2M worth of shares in EyePoint Pharmaceuticals, Inc. in June 2018
Jul 08, 2018
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
In The News
Aug 13, 2019 - RelSci
-EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Aug 08, 2019 - ENP Newswire
Aug 07, 2019 - SEC
Essex Woodlands Health Ventures focuses on diversified healthcare investing. They invest in the pharmaceutical, biotechnology, medical device, services and information technology sectors. They tend to focus on early-stage investments, but may also make later-stage investments including mature venture, growth equity and PIPE investment opportunities.
In The News
Essex Woodlands Management, Inc. sold $234M worth of shares in Corium International, Inc. in November 2018
Dec 08, 2018 - RelSci
Jul 19, 2018 - PR Newswire